NCT00875459已完成3 期
An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 1 Diabetes Mellitus
Biodel0 个研究点目标入组 233 人开始时间: 2007年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 233
- 主要终点
- The frequency of occurrence of hypoglycemia measured quarterly over one year.
研究概览
简要总结
Follow-on study to the VIAject™ 06J study to evaluate the long-term safety and efficacy of VIAject™ when used as prandial insulin in combination with Lantus® in subjects with type 1 diabetes mellitus.
The VIAject™ 06J study is the efficacy and safety study for insulin VIAject™ to demonstrate equivalent blood glucose control in patients with type 1 diabetes mellitus with insulin and regular human insulin as prandial insulin and to demonstrate an equivalent safety profile for VIAject™ in comparison to human insulin
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Completed the VIAject™-06J protocol
- •Informed consent must be obtained in writing for all subjects
排除标准
- •History of frequent severe hypoglycemia within the prior six months which prevent study participation at the discretion of the investigator
- •History of known hypersensitivity to any of the components in the study medication
- •Progressive disease likely to prove fatal
- •Known significant hepatic disease or serum AST or ALT values > 3 X upper limit of normal or bilirubin levels > 1.5 X upper limit of normal
- •Severe complications of diabetes mellitus including a history or finding of Stage III or IV diabetic retinopathy (see Appendix B), proteinuria > 2+ by urine dipstick, serum creatinine of >1.8 mg/dl for males or >1.5 mg/dl for females, history of renal transplant, severe peripheral vascular disease, which has resulted in amputation or recent onset of chronic foot ulcers or claudication, or the recent, clinically documented loss a pedal pulse.
- •History of moderate to severe ketoacidosis within the 3 months preceding screening for the study
- •Current drug or alcohol abuse, or a history which in the opinion of the Investigator will impair subject safety or protocol compliance.
- •Current significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease as evaluated by the Investigator
- •A sexually active woman of childbearing age not actively and consistently practicing birth control by using a medically accepted device or therapy or a woman intending to become pregnant during the study
- •Abnormal ECG, safety lab or physical examination results which, in the opinion of the investigator, render the participation of the subject in the study to be inappropriate or unsafe
- •A history of lack of compliance with medical instructions, recent drug or alcohol abuse, or other reasons which, in the opinion of the investigator, render the participation of the subject in the study to be inappropriate or unsafe
研究组 & 干预措施
VIAject™
Experimental
Single injection
干预措施: VIAject™ (Drug)
结局指标
主要结局
The frequency of occurrence of hypoglycemia measured quarterly over one year.
时间窗: 18 months for most subjects
次要结局
- Changes in total daily:prandial insulin dose, insulin dose, body weight, insulin antibody titers, the effects of insulin antibodies on glycemic control, individual and group mean %HbA1c measured quarterly and over one year.(18 months for most subjects)
研究者
相似试验
已完成
3 期
An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 2 Diabetes MellitusDiabetes MellitusNCT00875108Biodel116
已完成
4 期
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)Juvenile Idiopathic Arthritis (JIA)NCT01544114Amgen46
已完成
1 期
Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)Alpha1-Antitrypsin DeficiencyNCT02870348Grifols Therapeutics LLC4
已完成
不适用
Extension Clinical Study to Evaluate the Long-term Efficacy and Safety of Repeat Treatment of YVOIRE Contour Injected Into the Anteromedial Malar Region in Subjects Who Have Completed the LG-HACL014 StudyNormal, Healthy Adults With Moderate, Severe, or Very Severe Volume Loss of Anteromedial Malar Region Who Have Completed the LG-HACL014 StudyNCT02119793LG Life Sciences13
Unknown
3 期
A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004Parkinson's DiseaseNCT02615873Intec Pharma Ltd.460